A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral DensityRobert R. Recker, Stephen L. Myers, Michael A. Bolognese et al.|Journal of Bone and Mineral Research|2014Cited by 291